Stanford Clinical Trial Reveals Five-Day Fasting-Style Diet Significantly Reduces Crohn’s Disease Inflammation

Stanford researchers find a 5-day monthly fasting-mimicking diet reduces Crohn's symptoms and inflammatory markers. Read about this breakthrough clinical trial.

By: AXL Media

Published: Apr 4, 2026, 9:01 AM EDT

Source: Information for this report was sourced from ScienceDaily

Bridging the Nutritional Gap in Chronic Gut Health

For the approximately one million Americans living with Crohn’s disease, the lack of definitive dietary protocols has long been a source of frustration. However, a new national study published in Nature Medicine suggests that a structured, short-term eating plan may provide the relief that has eluded patients for decades. Researchers from Stanford Medicine demonstrated that a "fasting-mimicking diet" (FMD) can induce clinical benefits by strategically restricting calories for just five days a month. This approach targets the chronic inflammation of the digestive tract that typically causes debilitating symptoms like abdominal pain, weight loss, and cramping.

The Mechanics of a Monthly Dietary Tweak

The clinical trial monitored 97 participants with mild-to-moderate Crohn’s disease over a three-month period to determine if cyclical fasting could alter the disease's trajectory. Sixty-five of these patients followed a specific plant-based regimen, consuming between 700 and 1,100 calories for five consecutive days each month before returning to their standard diets. According to Dr. Sidhartha R. Sinha, the study’s senior author, the majority of the FMD group reported noticeable symptom improvement after just one cycle. This stands in contrast to the control group, where fewer than half of the participants saw similar gains, often attributed to natural disease fluctuations.

Measuring Biological Shifts Beyond Subjective Relief

The study’s significance lies in its ability to quantify physical changes within the body rather than relying solely on patient-reported outcomes. By analyzing blood and stool samples, the research team discovered that fecal calprotectin, a critical protein marker for intestinal inflammation, dropped significantly in those following the FMD. Furthermore, immune cells in these participants began producing fewer inflammatory signals, and there were measurable reductions in lipid mediators derived from fatty acids. These findings provide a biological "signature" that confirms the diet is doing more than just making patients feel better, it is actively calming the overactive immune response.